QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)

Exelixis (EXEL) Stock Forecast, Price & News

$19.35
+0.08 (+0.42%)
(As of 06/8/2023 ET)
Compare
Today's Range
$19.22
$19.60
50-Day Range
$18.17
$20.48
52-Week Range
$14.87
$22.47
Volume
1.53 million shs
Average Volume
2.90 million shs
Market Capitalization
$6.30 billion
P/E Ratio
40.31
Dividend Yield
N/A
Price Target
$25.33

Exelixis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
30.9% Upside
$25.33 Price Target
Short Interest
Healthy
2.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.63
Upright™ Environmental Score
News Sentiment
1.01mentions of Exelixis in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.03 M Sold Last Quarter
Proj. Earnings Growth
50.77%
From $0.65 to $0.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.11 out of 5 stars

Medical Sector

12th out of 981 stocks

Biological Products, Except Diagnostic Industry

3rd out of 163 stocks


EXEL stock logo

About Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Stock News Headlines

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (EXEL)
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Stifel Nicolaus Remains a Hold on Exelixis (EXEL)
Stifel Nicolaus Sticks to Their Hold Rating for Exelixis (EXEL)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Exelixis: If It Ain't Broke...
Exelixis Inc EXEL Stock Quote
Exelixis (NASDAQ: EXEL)
RBC Capital Keeps Their Buy Rating on Exelixis (EXEL)
Exelixis: Q1 Earnings Snapshot
Exelixis (EXEL) Receives a New Rating from Piper Sandler
8 Analysts Have This to Say About Exelixis
See More Headlines

EXEL Price History

EXEL Company Calendar

Last Earnings
5/09/2023
Today
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
Employees
1,223
Year Founded
1994

Price Target and Rating

Average Stock Price Forecast
$25.33
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+31.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$182.28 million
Pretax Margin
11.86%

Debt

Sales & Book Value

Annual Sales
$1.61 billion
Cash Flow
$0.62 per share
Book Value
$7.68 per share

Miscellaneous

Free Float
316,158,000
Market Cap
$6.28 billion
Optionable
Optionable
Beta
0.68

Social Links


Key Executives

  • Michael M. MorrisseyMichael M. Morrissey
    President, Chief Executive Officer & Director
  • Christopher J. SennerChristopher J. Senner
    Chief Financial Officer & Executive Vice President
  • Dana Aftab
    Chief Scientific Officer & Executive VP-Discovery
  • Vicki L. Goodman
    Chief Medical Officer & Executive Vice President
  • Jeffrey J. HessekielJeffrey J. Hessekiel
    Secretary, Executive VP & General Counsel













EXEL Stock - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EXEL shares.
View EXEL analyst ratings
or view top-rated stocks.

What is Exelixis' stock price forecast for 2023?

8 Wall Street analysts have issued twelve-month price objectives for Exelixis' shares. Their EXEL share price forecasts range from $20.00 to $32.00. On average, they predict the company's stock price to reach $25.33 in the next year. This suggests a possible upside of 30.0% from the stock's current price.
View analysts price targets for EXEL
or view top-rated stocks among Wall Street analysts.

How have EXEL shares performed in 2023?

Exelixis' stock was trading at $16.04 at the beginning of 2023. Since then, EXEL shares have increased by 21.5% and is now trading at $19.49.
View the best growth stocks for 2023 here
.

Are investors shorting Exelixis?

Exelixis saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 7,410,000 shares, an increase of 21.5% from the April 30th total of 6,100,000 shares. Based on an average trading volume of 3,050,000 shares, the days-to-cover ratio is presently 2.4 days.
View Exelixis' Short Interest
.

When is Exelixis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our EXEL earnings forecast
.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings results on Tuesday, May, 9th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by $0.05. The biotechnology company earned $408.79 million during the quarter, compared to analyst estimates of $427.91 million. Exelixis had a net margin of 9.24% and a trailing twelve-month return on equity of 6.20%.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.77 billion-$1.88 billion, compared to the consensus revenue estimate of $1.83 billion.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.14%), Farallon Capital Management LLC (7.22%), Renaissance Technologies LLC (4.70%), State Street Corp (3.98%), JPMorgan Chase & Co. (2.38%) and Price T Rowe Associates Inc. MD (1.85%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Dana Aftab, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends
.

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $19.49.

How much money does Exelixis make?

Exelixis (NASDAQ:EXEL) has a market capitalization of $6.35 billion and generates $1.61 billion in revenue each year. The biotechnology company earns $182.28 million in net income (profit) each year or $0.48 on an earnings per share basis.

How many employees does Exelixis have?

The company employs 1,223 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.

This page (NASDAQ:EXEL) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -